CAR T cell therapy for advanced cancers that can be targeted
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase study tests a lab-made immune cell treatment that is designed to find and attack tumors that show a specific target on cancer cells. It is for adults with advanced cancers that have not responded well to at least two standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 21 years or older and able to give written consent for study procedures and sample use
- Have a cancer that has spread and is resistant or not suitable for at least two prior standard treatments
- Have measurable tumor on scans (measurable by RECIST 1.1) and the cancer is known to show the NKG2D target on tumor cells
- Be well enough for treatment: ECOG 0–1 and life expectancy over 12 weeks
- Have lab values that show your liver, kidneys, and lungs can handle treatment, and your bone marrow is strong enough (blood counts meet set thresholds)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack tumors with specific markers (GD2 or CD70). It may be an option for patients whose cancer has not responded to standard treatments.
This trial tests a lab-made immune therapy (CAR T-cells) that targets CD19, a marker found on certain lymphoma and leukemia cells. It’s for people whose lymphoma or ALL came back or did not respond to standard treatments, with the goal of getting the treatment to attack the cancer.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.